You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Surveillance for Invasive Pneumococcal Disease During 20002005 in a Population of Children Who Received 7-Valent Pneumococcal Conjugate Vaccine

Black, Steven MD*; France, Eric K. MD†; Isaacman, Daniel MD‡; Bracken, Laura§; Lewis, Edwin MPH§; Hansen, John BA§; Fireman, Bruce MA§; Austrian, Robert MD∥; Graepel, Jay PhD‡; Gray, Sharon MS‡; Klein, Nicola P. MD, PhD§

Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e318124a494
Original Studies

Objectives: To assess the incidence of invasive pneumococcal disease (IPD) in all children younger than 5 years of age in the Northern California Kaiser Permanente (NCKP) health care system during a 5-year surveillance period (2000–2005) after the introduction in April 2000 of routine use of 7-valent pneumococcal conjugate vaccine (PCV7).

Methods: This was a laboratory-based surveillance study of all children younger than 5 years of age in the NCKP health care system from April 2000 to March 2005. The comparison group was all children younger than 5 years of age in the NCKP health care system from April 1996 to March 2000. Data obtained from clinical databases included microbiologic identification and susceptibility testing; serotyping of isolates; immunization records; and IPD diagnoses for inpatients and outpatients. IPD was defined as a positive culture of Streptococcus pneumoniae from a normally sterile body site.

Results: For all serotypes, the mean annual incidence of IPD during the postlicensure surveillance period was 15.3 cases/100,000 person-years (105 p-y) compared with 62.5 cases/105 p-y in the prelicensure years of 1996–2000. The average incidence of IPD caused by vaccine serotypes was reduced from 50.1 cases/105 p-y during the prelicensure years to 4.9 cases/105 p-y during the postlicensure period. The average incidences of IPD caused by cross-reactive and by nonvaccine serotypes were 5.8 and 5.3 cases/105 p-y, respectively, during the prelicensure years and 2.5 and 6.2 cases/105 p-y, respectively, during the postlicensure period. Of the 131 IPD cases observed during the postlicensure surveillance period, bacteremia (50.4%) and pneumonia (31.3%) were the most common diagnoses. During the 5-year postlicensure surveillance period, only 3 subjects who were identified to be fully vaccinated for age with PCV7 (3 doses by 7 months of age or 4 doses by 18 months of age) developed vaccine-serotype IPD.

Conclusion: The incidence of IPD has significantly decreased in a large population of children after the introduction of PCV7. Vaccine-type IPD was rare in patients who received full 4-dose immunization with PCV7. There is no clear evidence of a significant increase in nonvaccine-serotype IPD. Introduction of a 4-dose infant schedule of PCV7 into this population has resulted in a marked and sustained reduction of IPD in children.

Author Information

From the *Division of Pediatric Infectious Diseases, Stanford University School of Medicine, Stanford, CA; †Kaiser Permanente, Denver, CO; ‡Global Medical Affairs, Wyeth Pharmaceuticals, Collegeville, PA; §Kaiser Permanente Vaccine Study Center, Oakland, CA; and ∥University of Pennsylvania School of Medicine, Philadelphia, PA.

Accepted for publication May 23, 2007.

Address for correspondence: Nicola P. Klein, MD, PhD, Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16th floor, Oakland, CA 94612. E-mail:

© 2007 Lippincott Williams & Wilkins, Inc.